Letter to the Editor
Treatment of severe lichen planus with the JAK inhibitor tofacitinib

https://doi.org/10.1016/j.jaci.2020.01.031Get rights and content

First page preview

First page preview
Click to open first page preview

References (6)

There are more references available in the full text version of this article.

Cited by (28)

  • Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study

    2022, Journal of Investigative Dermatology
    Citation Excerpt :

    Type I MHC expression is dependent on pSTAT1, indicating that treatment with ruxolitinib resulted in decreased pSTAT1 levels (Zhou, 2009). Similarly, a small series of patients with severe LP were found to have elevated pSTAT1 and responded to oral tofacitinib, a JAK1/JAK3 inhibitor (Damsky et al., 2020). Our RNA-seq data revealed the expression patterns of 12 ISGs were reversed following treatment, showing a blockade of cytotoxic T-cell responses and induction of anti-apoptotic signaling.

  • Janus kinase inhibitors in dermatology: Part I. A comprehensive review

    2022, Journal of the American Academy of Dermatology
    Citation Excerpt :

    Two patients achieved complete or near-complete remission of disease on tofacitinib. The third patient had significant improvement on concomitant therapy with tofacitinib, prednisone, and methotrexate.15 No adverse events were reported.

  • The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases

    2021, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    JAK inhibitors have shown efficacy and are in phase 3 clinical trials in psoriasis (IL-17 and IL-23)38 and atopic dermatitis (IL-4 and IL-13).39-42 There is emerging evidence of the efficacy of JAK inhibitors for less common dermatologic disorders, including lichen planus, morphea, and granuloma annulare, among others (see Table E2 in this article's Online Repository at www.jacionline.org).43-48 Topically applied JAK inhibitors clearly have a role in dermatology and are being actively investigated (discussed later in this review).

View all citing articles on Scopus

This work was supported by the Ranjini and Ajay Poddar Fund for Dermatologic Diseases Research (B.K.). W.D. is supported by the Dermatology Foundation.

Disclosure of potential conflict of interest: W. Damsky has research funding from Pfizer, but it did not support this work, and is a consultant for Eli Lilly. B. King is an investigator for Concert Pharmaceuticals Inc, Eli Lilly and Company, and Pfizer Inc; is a consultant to and/or has served on advisory boards for Aclaris Therapeutics, Arena Pharmaceuticals, Bristol-Meyers Squibb, Concert Pharmaceuticals Inc, Dermavant Sciences, Eli Lilly and Company, Pfizer Inc, Regeneron, and Sanofi Genzyme; and is on speakers bureau for Pfizer Inc, Regeneron, and Sanofi Genzyme. The rest of the authors declare that they have no relevant conflicts of interest.

View full text